Recruiting
Phase 3

BIOxHEAL

Sponsor:

Applied Biologics, LLC

Code:

NCT07852338

Conditions

Diabetic Foot Ulcer

Amniotic Membrane Placental Allograft

Biologic

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Standard of Care

BIOxHEAL (human amniotic membrane allograft)

Study Details

Brief summary:

BIOxHEAL is an investigational placental-derived biologic being evaluated for the treatment of nonhealing diabetic foot ulcers. Adults with type 1 or type 2 diabetes who have a diabetic foot ulcer that has not healed with standard wound care may be eligible to participate. Participants in the randomized phase are assigned by chance in a 2:1 ratio to receive either BIOxHEAL administered topically in combination with standard of care (SOC), or SOC alone. Treatment is administered once weekly for up to 12 weeks or until complete ulcer closure. The primary objective is to evaluate whether BIOxHEAL plus SOC increases the proportion of target ulcers achieving complete closure at Week 12 compared with SOC alone.

Conditions

Diabetic Foot Ulcer

Amniotic Membrane Placental Allograft

Biologic

Study ID

NCT07852338

Start date

Oct 8, 2026

Status verified date

Oct, 2026

Completion date

Sep, 2027

Anticipated

Primary completion date

Sep, 2027

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Inclusion Criteria:

Participants must be at least 18 years of age or older. Participants must have a diagnosis of type 1 or 2 diabetes mellitus. At randomization (or enrollment for the sentinel cohort), participants must have a target ulcer with a minimum surface area of 1.0 cm2 and a maximum surface area of 25.0 cm2 measured post debridement.

The target ulcer must have been present for a minimum of 4 weeks and a maximum of 52 weeks of standard of care prior to the initial screening visit.

The target ulcer must be located on the foot with at least 50% of the ulcer below the malleolus.

The target ulcer must be Wagner Grade 1 extending at least through the dermis or subcutaneous tissue.

The affected limb must have adequate perfusion confirmed by vascular assessment. Any of the following methods performed within 3 months of the first screening visit are acceptable:

ABI greater than or equal to 0.7 and less than or equal to 1.3 TBI greater than or equal to 0.6 TCOM greater than or equal to 40 mmHg Arterial Doppler ultrasound with biphasic dorsalis pedis and posterior tibial vessels at the level of the ankle on the extremity where the index ulcer is located If the participant has two or more ulcers, they must be separated by at least 2 cm. The largest ulcer satisfying the inclusion and exclusion criteria will be designated as the target ulcer.

The participant must consent to using the prescribed offloading method for the duration of the study.

The participant must agree to attend the weekly study visits required by the protocol.

The participant must be willing and able to participate in the informed consent process.

The participant must have a suitable living environment to manage prescribed offloading and wound care management.

Exclusion Criteria:

Known life expectancy of less than 6 months. Target ulcer is not secondary to diabetes. Wagner Grade 2 to 5 ulcers. Target ulcer is infected, or there is cellulitis in the surrounding skin.

Evidence of osteomyelitis complicating the target ulcer, based on clinical assessment supported by at least one of the following:

Imaging (for example, plain radiography, MRI, or nuclear medicine study) consistent with osteomyelitis Positive bone culture Abnormal inflammatory markers (for example, ESR, CRP) in conjunction with clinical signs highly suggestive of osteomyelitis per Investigator judgment - Documentation of the basis for diagnosing or excluding osteomyelitis must be available in the participant's source documents Infection in the target ulcer or in a remote location that requires systemic antibiotic therapy.

Receiving immunosuppressants (including systemic corticosteroids at doses greater than 10 mg of prednisone per day or equivalent) or cytotoxic chemotherapy.

Topical application of steroids to the ulcer surface within one month of initial screening.

Previous partial amputation on the affected foot, if the resulting deformity impedes proper offloading of the target ulcer.

Glycated hemoglobin (HbA1c) greater than or equal to 12% within 3 months of the initial screening visit.

The surface area of the target ulcer has reduced in size by more than 40% between Screening Visit 1 and Treatment Visit 1 during the protocol-defined screening period.

Acute Charcot foot, or an inactive Charcot foot, that impedes proper offloading of the target ulcer.

Women who are pregnant or considering becoming pregnant within the next 6 months.

Male or female participants who are unwilling or unable to comply with the required contraceptive measures for the duration of study participation.

End stage renal disease requiring dialysis. Serum creatinine level greater than 3.0 mg/dL. Aspartate aminotransferase (AST, GOT) and/or alanine aminotransferase (ALT, GPT) greater than 3 times the upper limit of normal.

A medical or psychological condition that, in the opinion of the investigator, may interfere with study assessments.

Treated with hyperbaric oxygen therapy or a Cellular and/or Tissue Product (CTP) in the 30 days prior to the initial screening visit.

Mini Nutritional Assessment (MNA) screening score below 12.

Study Design

Enrollment

253 participants

Anticipated

Allocation

Randomized

Intervention Model

Parallel Assignment

Primary purpose

Treatment

Interventions and Outcome Measures

Arms

experimental: Sentinel Cohort: BIOxHEAL + SOC

Non-randomized sentinel cohort (5 completed participants required, up to 10 enrolled). Participants receive BIOxHEAL administered topically once weekly plus SOC for up to 12 weeks or until complete ulcer closure, to assess early safety before the randomized phase.

active comparator: Randomized: SOC Alone

Participants randomized 2:1 to receive protocol-defined SOC alone, with weekly treatment visits for up to 12 weeks or until complete ulcer closure, with closure confirmed approximately 2 weeks later.

experimental: Randomized: BIOxHEAL + SOC

Participants randomized 2:1 to receive BIOxHEAL administered topically once weekly plus SOC for up to 12 weeks or until complete ulcer closure, with closure confirmed approximately 2 weeks later.

Interventions

Standard of Care

Protocol-defined standard of care (SOC) for diabetic foot ulcers, performed at each study visit: wound cleansing with sterile saline, sharp debridement as clinically indicated, a non-adherent silicone primary dressing with an absorbent secondary dressing to maintain a moist wound environment, offloading for plantar and pressure-bearing ulcers (Foot Defender boot, Total Contact Cast, or Medical Monitor-approved equivalent), and diabetes education and nutritional support, including smoking cessation counseling for current smokers.

BIOxHEAL (human amniotic membrane allograft)

BIOxHEAL is an investigational, sterile, single-use biologic derived from human amniotic membrane. BIOxHEAL is administered topically to the target ulcer once weekly in combination with protocol-defined standard of care for up to 12 weeks or until complete ulcer closure. Each unit is individually packaged for single-patient, one-time use.

Primary outcome measure

  • Proportion of target ulcers with complete wound closure at Week 12 [ Time Frame: Baseline to Week 12 ]

Central Contacts and Locations

Central contacts

Locations

NOMS Ankle and Foot Care Center

Recruiting

Boardman, Ohio, United States, 44512

Contacts

Lawrence DiDomenico, DPM

330-953-3222ld5353@aol.com

More Information

Sponsor

Applied Biologics, LLC

Last update posted

Oct 16, 2026

Last verified

Oct, 2026

Keywords

  • Diabetic Foot Ulcer
  • Chronic Wound Wound Healing

Trial information was received from ClinicalTrials.gov and was last updated on 2026-11-16. This information was provided to ClinicalTrials.gov by Applied Biologics, LLC on 2026-10-16. Recruitment status is synced daily from ClinicalTrials.gov and may not reflect the sponsor's current status. Confirm during your call.